These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 22453135)

  • 1. Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes.
    Sede M; Ojeda D; Cassino L; Westergaard G; Vazquez M; Benetti S; Fay F; Tanno H; Quarleri J
    Antiviral Res; 2012 May; 94(2):184-7. PubMed ID: 22453135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of hepatitis virus B isolated from a multi-drug refractory patient.
    Wei C; Chong YT; Wen JZ; Li YW; Li G
    Virus Res; 2011 Jan; 155(1):254-8. PubMed ID: 20970466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
    Salpini R; Svicher V; Cento V; Gori C; Bertoli A; Scopelliti F; Micheli V; Cappiello T; Spanò A; Rizzardini G; De Sanctis GM; Sarrecchia C; Angelico M; Perno CF
    Antiviral Res; 2011 Nov; 92(2):382-5. PubMed ID: 21920388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].
    Liang PP; Guo JJ; Li QL; Luo Q; Shi XF; Huang AL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):516-20. PubMed ID: 22152243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
    Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX
    Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
    Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
    Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B; Wei L; Chen M; Wang L
    Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
    Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing.
    Han Y; Zhang Y; Mei Y; Wang Y; Liu T; Guan Y; Tan D; Liang Y; Yang L; Yi X
    J Virol Methods; 2013 Nov; 193(2):341-7. PubMed ID: 23773806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
    Taramasso L; Caligiuri P; Di Biagio A; Bruzzone B; Rosso R; Icardi G; Viscoli C
    J Med Virol; 2011 Nov; 83(11):1905-8. PubMed ID: 21915864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.
    Liu BM; Li T; Xu J; Li XG; Dong JP; Yan P; Yang JX; Yan L; Gao ZY; Li WP; Sun XW; Wang YH; Jiao XJ; Hou CS; Zhuang H
    Antiviral Res; 2010 Mar; 85(3):512-9. PubMed ID: 20034521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.